Abstract
PURPOSE: To evaluate the therapeutic efficacy and safety of percutaneous radiofrequency (RF) ablation for recurrent hepatocellular carcinoma (HCC) in the liver after hepatectomy. MATERIALS AND METHODS: Forty-five patients with 53 recurrent HCC tumors in the liver underwent percutaneous RF ablation with ultrasonographic guidance. All patients had a history of hepatic resection for HCC. The mean diameter of recurrent tumors was 2.1 cm (range, 0.8-4.0 cm). All patients were followed up for at least 10 months after ablation (range, 10-40 months; mean, 23 months). Therapeutic efficacy and complications were evaluated with multiphase helical computed tomography (CT) at regular follow-up visits. Overall and disease-free survival rates were calculated. RESULTS: At follow-up CT after initial RF ablation, 11 (21%) of 53 ablated HCC tumor sites showed residual tumor or local tumor progression. After additional RF ablation, complete ablation of 46 (87%) of 53 tumors was attained. Also at initial follow-up CT, before either additional RF ablation or other treatment was performed, 21 (47%) of 45 patients were found to have 41 new HCC tumors at other liver sites. Of these, nine tumors in eight patients were treatable with a second application of RF ablation. Overall survival rates at 1, 2, and 3 years were 82%, 72%, and 54%, respectively. No deaths or complications requiring further treatment occurred as a result of RF ablation. CONCLUSION: Percutaneous RF ablation is an effective and safe method for treating recurrent HCC in the liver after hepatectomy, with a good overall patient survival rate.
| Original language | English |
|---|---|
| Pages (from-to) | 135-141 |
| Number of pages | 7 |
| Journal | Radiology |
| Volume | 230 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2004 Jan 1 |
| Externally published | Yes |
Fingerprint
Keywords
- Liver neoplasms, therapy
- Liver, interventional procedures
- Liver, surgery
- Radiofrequency (RF) ablation
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
Cite this
Recurrent Hepatocellular Carcinoma : Percutaneous Radiofrequency Ablation after Hepatectomy. / Choi, Dongil; Lim, Hyo K.; Kim, Min Ju; Lee, Sung Hoon; Kim, Seung Hoon; Lee, Won Jae; Lim, Jae Hoon; Joh, Jae Won; Kim, Yong Il.
In: Radiology, Vol. 230, No. 1, 01.01.2004, p. 135-141.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Recurrent Hepatocellular Carcinoma
T2 - Percutaneous Radiofrequency Ablation after Hepatectomy
AU - Choi, Dongil
AU - Lim, Hyo K.
AU - Kim, Min Ju
AU - Lee, Sung Hoon
AU - Kim, Seung Hoon
AU - Lee, Won Jae
AU - Lim, Jae Hoon
AU - Joh, Jae Won
AU - Kim, Yong Il
PY - 2004/1/1
Y1 - 2004/1/1
N2 - PURPOSE: To evaluate the therapeutic efficacy and safety of percutaneous radiofrequency (RF) ablation for recurrent hepatocellular carcinoma (HCC) in the liver after hepatectomy. MATERIALS AND METHODS: Forty-five patients with 53 recurrent HCC tumors in the liver underwent percutaneous RF ablation with ultrasonographic guidance. All patients had a history of hepatic resection for HCC. The mean diameter of recurrent tumors was 2.1 cm (range, 0.8-4.0 cm). All patients were followed up for at least 10 months after ablation (range, 10-40 months; mean, 23 months). Therapeutic efficacy and complications were evaluated with multiphase helical computed tomography (CT) at regular follow-up visits. Overall and disease-free survival rates were calculated. RESULTS: At follow-up CT after initial RF ablation, 11 (21%) of 53 ablated HCC tumor sites showed residual tumor or local tumor progression. After additional RF ablation, complete ablation of 46 (87%) of 53 tumors was attained. Also at initial follow-up CT, before either additional RF ablation or other treatment was performed, 21 (47%) of 45 patients were found to have 41 new HCC tumors at other liver sites. Of these, nine tumors in eight patients were treatable with a second application of RF ablation. Overall survival rates at 1, 2, and 3 years were 82%, 72%, and 54%, respectively. No deaths or complications requiring further treatment occurred as a result of RF ablation. CONCLUSION: Percutaneous RF ablation is an effective and safe method for treating recurrent HCC in the liver after hepatectomy, with a good overall patient survival rate.
AB - PURPOSE: To evaluate the therapeutic efficacy and safety of percutaneous radiofrequency (RF) ablation for recurrent hepatocellular carcinoma (HCC) in the liver after hepatectomy. MATERIALS AND METHODS: Forty-five patients with 53 recurrent HCC tumors in the liver underwent percutaneous RF ablation with ultrasonographic guidance. All patients had a history of hepatic resection for HCC. The mean diameter of recurrent tumors was 2.1 cm (range, 0.8-4.0 cm). All patients were followed up for at least 10 months after ablation (range, 10-40 months; mean, 23 months). Therapeutic efficacy and complications were evaluated with multiphase helical computed tomography (CT) at regular follow-up visits. Overall and disease-free survival rates were calculated. RESULTS: At follow-up CT after initial RF ablation, 11 (21%) of 53 ablated HCC tumor sites showed residual tumor or local tumor progression. After additional RF ablation, complete ablation of 46 (87%) of 53 tumors was attained. Also at initial follow-up CT, before either additional RF ablation or other treatment was performed, 21 (47%) of 45 patients were found to have 41 new HCC tumors at other liver sites. Of these, nine tumors in eight patients were treatable with a second application of RF ablation. Overall survival rates at 1, 2, and 3 years were 82%, 72%, and 54%, respectively. No deaths or complications requiring further treatment occurred as a result of RF ablation. CONCLUSION: Percutaneous RF ablation is an effective and safe method for treating recurrent HCC in the liver after hepatectomy, with a good overall patient survival rate.
KW - Liver neoplasms, therapy
KW - Liver, interventional procedures
KW - Liver, surgery
KW - Radiofrequency (RF) ablation
UR - http://www.scopus.com/inward/record.url?scp=0346218105&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0346218105&partnerID=8YFLogxK
U2 - 10.1148/radiol.2301021182
DO - 10.1148/radiol.2301021182
M3 - Article
C2 - 14631050
AN - SCOPUS:0346218105
VL - 230
SP - 135
EP - 141
JO - Radiology
JF - Radiology
SN - 0033-8419
IS - 1
ER -